All In Biotech

Drug Trial Radar · NCT06108219

A Phase 2b, Study Evaluating Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients With Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

Last checked: Nov 20, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 175 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

175

Actual

Start

Oct 25, 2023

Primary completion

Feb 13, 2026

Study completion Aug 24, 2026

Sponsor

Lead sponsor
Corcept TherapeuticsIndustry
Sponsor type
Industry
First posted
Oct 30, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Miricorilant in Adult Patients with Nonalcoholic Steatohepatitis/Metabolic Dysfunction-Associated Steatohepatitis (MONARCH)

Conditions

  • Nonalcoholic Steatohepatitis (NASH)
  • Metabolic Dysfunction-associated Steatohepatitis (MASH)

Interventions

  • Miricorilant (Cohort A)Drug

    Miricorilant 100 mg for oral dosing

  • Placebo (Cohort A)Drug

    Matching placebo for oral dosing for 48 Weeks

  • Miricorilant (Cohort B)Drug

    Miricorilant 100 mg for oral dosing Miricorilant 200 mg for oral dosing

  • Placebo (Cohort B)Drug

    Matching placebo for oral dosing for 24 Weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent relative change from Baseline in liver-fat content assessed by MRI-PDFF (Cohort A and Cohort B)Time frame: Week 24

Locations

77 sites in 3 countries. Site status is shown where the registry gives one.

  • Site #207

    Chandler, Arizona

  • Site #209

    Tucson, Arizona

  • Site #378

    Huntington Park, California

  • Site #439

    Lancaster, California

  • Site #469

    Long Beach, California

  • Site #373

    Los Angeles, California

  • Site #214

    Panorama City, California

  • Site #233

    Santa Ana, California

  • Site #452

    Boca Raton, Florida

  • Site # 101

    Gainesville, Florida

  • Site #465

    Hallandale, Florida

  • Site #430

    Hialeah Gardens, Florida

  • Site #458

    Lakewood Rch, Florida

  • Site #475

    Largo, Florida

  • Site #438

    Miami Lakes, Florida

  • Site #460

    Viera, Florida

  • Site #453

    Houma, Louisiana

  • Site #451

    Marrero, Louisiana

  • Site #061

    Metairie, Louisiana

  • Site #440

    Rockville, Maryland

  • Site #442

    Saint Paul, Minnesota

  • Site #228

    Kansas City, Missouri

  • Site #455

    Jackson, New Jersey

  • Site #445

    East Syracuse, New York

  • Site #454

    New York, New York

  • Site #464

    Morehead City, North Carolina

  • Site #447

    Beavercreek, Ohio

  • Site #470

    Columbus, Ohio

  • Site #448

    Dayton, Ohio

  • Site #437

    Westlake, Ohio

  • Site #461

    Cordova, Tennessee

  • Site # 546

    Arlington, Texas

  • Site #545

    Austin, Texas

  • Site #211

    Austin, Texas

  • Site #432

    Brownsville, Texas

  • Site #370

    Dallas, Texas

  • Site #213

    Edinburg, Texas

  • Site #215

    Edinburg, Texas

  • Site #431

    Georgetown, Texas

  • Site # 066

    Houston, Texas

Showing 40 of 77 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.